Galapagos NV (GXE.F)
- Simply Wall St.
Galapagos First Quarter 2024 Earnings: EPS: €0.36 (vs €0.35 in 1Q 2023)
Galapagos ( AMS:GLPG ) First Quarter 2024 Results Key Financial Results Revenue: €62.4m (down 65% from 1Q 2023). Net...
- GlobeNewswire
Galapagos reports first quarter 2024 financial results
Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunologyExecuted agreements with BridGene Biosciences and Thermo Fisher Scientific, and investment in Frontier MedicinesTransferred Jyseleca® business to Alfasigma S.p.A., freeing up resources to invest in growth areasGroup net revenues in the first quarter of €100 millionCash and current financial investments of €3.6 billion on 31 March 202
- GlobeNewswire
Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024
Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the company’s Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) held on 30 April 2024 were approved. The AGM approved, amongst other items: The Remuneration Report and revised Remuneration PolicyThe remuneration of the members of the Board of DirectorsThe reappointment of Dr. Elisabeth Svanberg as Independent Non-Executive Director The appointments of D
